# Heze Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/heze-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Hangzhou, China
- Website: www.hezepharm.com
- Latest round: Series A (Aug 22, 2016)
- Investors on record: 3

## About

Established in 2006 and based in Hangzhou, China, Heze Pharmaceutical is a pharmaceutical enterprise engaged in drug certification and conversion. It has partnerships with Huadong Medicine, Minsheng Pharma, Yongning Pharm, etc. Its subsidiaries include Hehui Pharmaceutical, Kunyuan Pharmaceutical, Yiyuan Pharmaceutical, etc. In 2021, it jointly established Hangzhou Heze Yuanzhi Chinese Medicine Technology with Zhejiang University of Traditional Chinese Medicine. In 2022, it established a subsidiary in Zhongshan. In September 2023, Heze Pharmaceutical raised strategic investment funding from new investors China Capital Management, JIC Investment, Zhejiang Fu Zhe Capital Management, and Zhengzhou Hi-Tech Industrial Investment Fund.

The company has a series of MAH-licensed products, covering innovative drugs, improved new drugs, and difficult generic drugs. It also developed the peptide drug R&D platform, small molecule drug R&D platform, liquid formulation platform, solid formulation R&D platform, reverse engineering platform, and clinical trial service platform.

## Funding rounds

- Series A, Aug 22, 2016 — Yonghua Capital, Haibang Venture, HEO Ventures

## Investors

- Yonghua Capital (https://capitalatlas.ai/funds/yonghua-capital) — Series A
- Haibang Venture — Series A
- HEO Ventures — Series A